CriticalReversible MAO-A inhibitor (RIMA)×Selective 5-HT1B/1D serotonin receptor agonist
Updated · Methodology
Mechanism
Monoamine oxidase type A (MAO-A) is the main enzyme that breaks down sumatriptan, and moclobemide reversibly inhibits mainly this enzyme (sumatriptan summary of product characteristics, SmPC, section 5.2; moclobemide SmPC, section 5.1). An MAO-A inhibitor doubled the area under the concentration curve (AUC) of subcutaneous sumatriptan and raised systemic exposure after a 25 mg sumatriptan tablet about 7-fold. The effect is greater with oral sumatriptan because of first-pass metabolism in the gut and liver (sumatriptan label, US Food and Drug Administration, FDA, section 12.3). Sumatriptan stimulates vascular serotonin 5-HT1D receptors, which take part in the constriction of cranial blood vessels (sumatriptan SmPC, section 5.1). The moclobemide SmPC contraindicates all triptans because MAO and cytochrome P450 enzymes break them down, so their concentrations rise with moclobemide (section 4.5).
Symptoms
The Spanish sumatriptan summary of product characteristics (SmPC) does not describe how this combination presents and only warns that an interaction with monoamine oxidase (MAO) inhibitors is possible (section 4.5). With MAO inhibitors, serotonin syndrome may occur: agitation, hallucinations, coma, fast heart rate, labile blood pressure, high temperature, overactive reflexes, poor coordination, nausea, vomiting and diarrhoea. It usually starts within minutes to hours of a new or higher dose of a serotonergic drug (sumatriptan label, US Food and Drug Administration, FDA, section 5.7). Sumatriptan itself can cause pain, sensations of heat or cold, pressure and tightness in any part of the body, including the chest and throat, and these sensations are sometimes intense. It can also cause a transient rise in blood pressure soon after a dose. The SmPC lists coronary artery vasospasm, angina and myocardial infarction among reactions of unknown frequency (sumatriptan SmPC, section 4.8). On rare occasions triptans have caused a marked rise in blood pressure, up to hypertensive crisis with acute impairment of organ systems, including in people with no history of hypertension (FDA sumatriptan label, section 5.8).
Management
The combination is contraindicated. The moclobemide summary of product characteristics (SmPC) contraindicates triptans and names sumatriptan explicitly (sections 4.3 and 4.5), and the sumatriptan SmPC contraindicates monoamine oxidase (MAO) inhibitors (sections 4.3 and 4.5). The US Food and Drug Administration (FDA) sumatriptan label also contraindicates MAO type A inhibitors, because they raise systemic exposure to sumatriptan tablets 7-fold (sections 4 and 7.2). Do not use sumatriptan within 2 weeks of stopping moclobemide (sumatriptan SmPC, section 4.3; FDA label, section 4). The documents give the same interval for reversible and irreversible MAO inhibitors. No document says how long to wait before starting moclobemide after sumatriptan. If the two drugs have nevertheless been taken together and signs of serotonin syndrome appear, stop sumatriptan (FDA sumatriptan label, section 5.7). For moclobemide, consider a lower dose or stopping it, depending on how severe the symptoms are (moclobemide SmPC, section 4.4). Monitor blood pressure during sumatriptan treatment (FDA sumatriptan label, section 5.8). Sumatriptan is contraindicated in moderate and severe hypertension and in uncontrolled mild hypertension (sumatriptan SmPC, section 4.3). If chest pain and tightness suggest cardiac ischaemia, withhold further sumatriptan doses and assess the patient (sumatriptan SmPC, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Moclobemida, Manerix 300 mg (nº registro 60824) (2025)– AEMPS, CIMA, nº registro 60824 (Manerix 300 mg comprimidos recubiertos con película), revisión 06/2025, secciones 4.3, 4.5, 5.1 y 5.2
- AEMPS: Ficha técnica: Sumatriptán, Imigran Neo 50 mg (nº registro 66406), sección 4.3 (2025)– AEMPS, CIMA, nº registro 66406 (Imigran Neo 50 mg comprimidos recubiertos con película, GlaxoSmithKline), revisión 10/2025 (la sección 10 indica 08/2025), secciones 4.3, 4.4, 4.5, 4.8 y 5.2
- FDA: IMITREX tablets (sumatriptan) prescribing information (2025)– FDA, DailyMed setid 584abe73-8290-4484-ff8e-5890831c095e (GlaxoSmithKline), revisión 12/2025 (versión 24), secciones 4, 5.7, 5.8, 7.2 y 12.3